DIA 2023

GLOBAL ANNUAL MEETING

BOSTON, MA | JUNE 25-29

ILLUMINATE

PRESS KIT

DIA 2023
GLOBAL ANNUAL MEETING
BOSTON, MA | JUNE 25-29

PRESS KIT

TABLE OF CONTENTS

ABOUT THE *DIA 2023 GLOBAL ANNUAL MEETING*

For more than 50 years, DIA has provided a neutral and transparent global forum for the exchange of ideas to further scientific and medical innovation. Fueled by the collaboration of thousands of attendees, the *DIA 2023 Global Annual Meeting (DIA 2023)* will bring industry, regulators, academics, and patients together to illuminate solutions to global and local challenges in the life sciences community.

DIA 2023 is the essential meeting for catalyzing knowledge creation to ignite healthcare product development. This unparalleled experience combines education and networking opportunities to elevate your skills and knowledge.

The goal of *DIA 2023* is to shine a light on different voices and highlight expertise across the globe. *DIA 2023* is more than a meeting, it's where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today's hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections. Through 170+ sessions spanning over 13 unique educational tracks, attendees will have the opportunity to learn more about their field or dive deep into a new topic of interest to broaden their knowledge.

DIA LEADERSHIP

Executive Leadership Team

- **Marwan Fathallah, MBA** – President and Global Chief Executive
- **Jack Foster, MBA** – Chief Financial Officer
- **Courtney Granville, PhD, MSPH** – Director, Scientific Affairs
- **Timothy Hess** – Vice President of IT
- **Katie Hill, MAT** – Senior Vice President & Managing Director, Learning & Digital Solutions
- **Anna McDermott-Vitak, MBA** – Senior Vice President & Managing Director, DIA Americas
- **Ania Mitan, MBA, MPharma** – Senior Vice President & Managing Director, DIA EMEA, India and Singapore
- **Shogo Nakamori, MBA, MPharma** – Senior Vice President & Managing Director, DIA Japan
- **Katie Truong, MBA** – Vice President, People & Culture
- **Tong-Yan Wang, MBA, PhD** – Senior Vice President & Managing Director, DIA China

Board of Directors

- **Cynthia L Verst, PharmD, MS** – Chair of DIA Board & Chair of Executive Committee
- **Judith Ng-Cashin, MD** – Immediate Past Chair & Chair of Governance Committee
- **Michael Rosenblatt, MD** – Chair-Elect & Senior Partner at Flagship Pioneering
- **Michael Romano** – Secretary/Treasurer & Chair of Finance Committee
- **Junaid Bajwa, MD** – DIA Director
- **Michael Devoy, MD** – DIA Director
- **Marwan Fathallah, MSE, MBA** – President and Global Chief Executive of DIA
- **Peter Honig, MD, MPH** – DIA Director
- **Frank N. Jiang, MD, PhD** – DIA Director
- **Tatyana Kosheleva, CPA** – DIA Director, Chair of Audit Committee, and CFO/Executive Board Member at Amring Pharmaceuticals Inc.
- **Peter Sorger, PhD** – DIA Director and Otto Krayer Professor of Systems Pharmacology at Harvard Medical School
- **Kihito Takahashi, MD, PhD** – DIA Director and Director and Chief Operating Officer of bio-tech venture BONAC Corporation in Japan
- **Karin Van Baelen** – DIA Director and head of the Global Regulatory Affairs organization at Janssen
- **Rachel Zhang, MBA** – DIA Director with two decades of Healthcare Consulting and Life Science Management experience
- **Jason Monteleone, CPA, CMA, MBA** – DIA Observer

Advisory Councils

- **Gerald J. Dal Pan, MD** – Chair, Council of Regulators Liaison Committee, US Food and Drug Administration Liaison to the DIA Board
- **Peter Bachmann, PhD** – Council of Regulators Liaison Committee, European Regulatory Network Liaison to the DIA Board
- **Yoshiaki Uyama, PhD** – Council of Regulators Liaison Committee, Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board
- **Catherine Parker** – Council of Regulators, Health Canada Liaison to the DIA Board
- **Mike Ward** – Council of Regulators, World Health Organization Liaison to the DIA Board
- **Yee Hoo Looi, PhD** – Council of Regulators, Health Sciences Authority Singapore Liaison to the DIA Board
- **Nam-Hee Lee, PhD** – Council of Regulators, Ministry of Food and Drug Safety Liaison to the DIA Board
- **Craig Lipset, MBA** – Chair, Regional Advisory Council, Americas
- **Jingsong Wand, MD** – Chair, Regional Advisory Council, China
- **Maren von Fritschen, PhD** – Chair, Regional Advisory Council, EMEA
- **Kazumichi Kobayashi, RPh** – Chair, Regional Advisory Council, Japan

KEYNOTE SPEAKERS AND PLENARY

Revolutionizing Life Sciences: How Diversity, Innovation, and AI are Accelerating the Future of Health

This keynote plenary promises to be a captivating and thought-provoking panel discussion. Beginning with our opening plenary, continuing with our DIAmond sessions and throughout each of the five meeting days, attendees will be taken on a journey exploring how diversity, innovation, and artificial intelligence are transforming the life sciences industry and accelerating the future of health.

PLENARY SPEAKERS

Keynote Speaker and Moderator Junaid Bajwa, MD

Chief Medical Scientist, Microsoft Research

Junaid is the Chief Medical Scientist at Microsoft Research and a practicing physician in the UK's National Health Service. Junaid has worked across primary care, secondary care, and public health settings in addition to acting as a payer, and policymaker within the UK, where he specialized in informatics, digital transformation, and leadership. He has consulted for health care systems across the US, Europe, Australia, the Middle East, Singapore, and Europe. Academically, he is a Clinical Associate Professor at UCL (University College London), and Visiting Scientist at the Harvard School of Public Health.

Amir Kalali, MD

Co-Chair, Decentralized Trials and Research Alliance (DTRA)

Dr. Kalali is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is a board director of both private and publicly traded companies and advises companies in the life sciences and technology sectors, universities, and investment groups. Dr. Kalali is the Co-Chair of the Decentralized Trials and Research Alliance (DTRA), and the Chairman and Chief Curator of the CNS Summit.

Armen Mkrtchyan, PhD

Senior Principal, Flagship Pioneering

Armen works to institutionalize and expand the use of Artificial Intelligence (AI) across Flagship and portfolio companies, and to help drive Flagship's efforts in AI research to identify breakthrough innovation platforms in human health and sustainability. Armen also works with the Preemptive Medicine and Health Security Initiative to define the strategic vision, and to identify partnerships and opportunities for whitespace innovation.

Zak Kohane, PhD

Harvard Medical School, United States, Chair, Department of Biomedical Informatics

Dr. Kohane is the inaugural chair of Harvard Medical School's Department of Biomedical Informatics, whose mission is to develop the methods, tools, and infrastructure required for a new generation of scientists and care providers to move biomedicine rapidly forward by taking advantage of the insight and precision offered by big data. Kohane develops and applies computational techniques to address disease at multiple scales, from whole health care systems to the functional genomics of neurodevelopment.

Najat Khan, PhD

Janssen Pharmaceutical Companies of Johnson & Johnson, United States
Chief Data Science Officer and Global Head, Strategy and Operations, R&D

Najat Khan, Ph.D., holds a unique combination of leadership roles at Janssen. As Chief Data Science Officer for R&D, Najat leads a team leveraging AI, machine learning, real-world data, and digital health across Janssen's pharmaceutical pipeline. As Global Head of Strategy & Operations for R&D, Najat shapes Janssen's R&D strategy, including pipeline decisions and strategic initiatives. This work advances the company's mission of driving transformational innovation for patients and changing the trajectory of healthcare.

HONORARY CO-CHAIRS

June Raine, MD, MSc, FRCP

Chief Executive, Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Dr. June Raine is the CEO of the Medicines and Healthcare products Regulatory Agency. Dr. Raine trained in general medicine in Oxford after completing a master's degree in research in pharmacology. Her interest in drug safety led to a career in medicines regulation from 1985 onwards. She was Director of the Vigilance and Risk Management of Medicines division from 2006. Her experience includes chairing the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency for six years. She is also a member of the WHO Advisory Committee on Safety of Medicinal Products.

David Mukanga, PhD, MPH

Deputy Director, Africa Regulatory Systems, Bill & Melinda Gates Foundation

Dr. David Mukanga is Deputy Director Africa Regulatory Systems at the Bill & Melinda Gates Foundation, where he leads the foundation's Africa regulatory systems optimization portfolio, and the linkage between regulatory systems and health care services. In this role, Dr. Makunga supports the development of harmonized, transparent, and predictable regulatory systems covering the lifecycle of medical products in Africa across the national, regional, and continental levels of the ecosystem. His work also involves support for regulatory emergency preparedness. In this role he works side by side with partners on the African continent to facilitate development of new medical products, as well as patient access to quality essential medicines.

KEY TRACKS

TRACK 1

Clinical Safety and Pharmacovigilance

This track provides an overview of the global regulatory environment in the field of clinical safety and pharmacovigilance for medical products (biopharmaceutical products, advanced therapies, and medical devices), with a focus on pragmatic approaches to protecting patient safety and incorporating the patient voice into the complex and evolving pharmacovigilance ecosystem. Forward-thinking sessions address the application of new technologies and methods to streamline pharmacovigilance systems and processes to enhance protection of patient safety as products become more complex, new data sources drive new analytical techniques, regulatory requirements become more detailed, and medical product development becomes more global.

TRACK 2

Clinical Trials and Clinical Operations

This comprehensive track covers the latest advances in clinical research and operations. Sessions cover innovative design strategies, establishing efficiencies in operations, and effective integration of patient outcomes in clinical trial design. Stakeholders will also discuss current and innovative methods to evaluate technology advances and systems to support clinical research programs cross-functional management integration, clinical utility, and endpoint development with the use of digital technology.

TRACK 3

Data and Technology

Innovative technologies are improving efficiency in the collection of data from clinical trials through the product development lifecycle to patients. This track focuses on recent developments in clinical data curation, data development, and harnessing data across the product lifecycle which includes the structure, organization, validation, storage, extraction, and delivery of diverse types of patient data to facilitate review, analysis, and reporting in regulatory submissions. Specifically, the track will have the following as focal points:

- Current and innovative methods to evaluate technology advances and systems to support clinical research programs cross-functional management integration, clinical utility, and endpoint development with the use of mobile/digital technology
- Structured and unstructured data sources
- Data Quality
- Blockchain technology and cloud computing
- Data Standards
- Real-World Data/Evidence
- Mobile/wearable technologies
- Informatic solutions and machine learning
- Endpoints: evolving data requirements to support new endpoints
- Data visualization
- DEI – strategies to ensure representative and unbiased data

TRACK 4

Medical Affairs and Scientific Communication

This track will share global insights from medical communication professionals, across the industry. Sessions will address best practices and emerging trends for delivering value across internal and external customers and collaborators. The aim of this track is enhancing cross-functional professional skillsets, including project management and leading effective teams.

TRACK 5

Patient Engagement

This track addresses meaningful patient engagement in medical product development, from early product development, and approval, through maintenance phases. It focuses on important questions for all stakeholders, including:

- How do we meaningfully engage patients and incorporate their voices into decision-making throughout the medical product lifecycle?
- How do we become truly patient-and-people-centric in our approach?
- How do we operationalize patient-centric approaches in our day-to-day work?
- How can we measure the effectiveness of our efforts, both for patient outcomes and to meet the needs of other stakeholders such as industry and regulatory decision-makers?
- What have we learned that can be used to drive more meaningful patient engagement?
- How do stakeholders best work together to leverage their collective power and expertise to promote meaningful involvement of patients?

TRACK 6

Translational Sciences and Precision Medicine

Preclinical and early-phase clinical research provides initial dosing and safety data for new drugs. This track focuses on the latest strategies used in early-stage compound selection, updates on safety considerations for both drugs and biologics, how PK/PD affects dosing strategies, and methods to improve data quality and integrity for proper downstream decision-making.

TRACK 7

Project Management and Strategic Planning

This track will illustrate best practices to improve project and program execution, strategic planning, and portfolio management. Sessions will highlight how to collaborate more effectively with internal and external stakeholders to achieve optimal efficiencies in project and program development. DIA recommends this track and associated sessions to professionals involved in or interested in making a career move into project management, portfolio management, and decision-making, alliance management, clinical development, clinical operations, marketing/commercialization, and CROs/Vendors. Topics related to bioethical issues are also welcome and may be considered for a special track in the meeting.

TRACK 8

R&D Quality and Compliance

This track provides a comprehensive view of the quality landscape across the preclinical, clinical, and pharmacovigilance domains within the biopharmaceutical industry. Sessions are focused on discussing innovative and risk-proportionate approaches to managing quality that are appropriate to an evolving development paradigm and in a global context. Sessions will address key topics in GLP (Good Laboratory Practice), GCP, and PV quality, providing knowledge and resources needed to implement pragmatic, proactive, and effective quality management.

TRACK 9

Regulatory

This track is composed of sessions addressing global laws, regulations, guidelines, and guidance's that govern prescription biopharmaceutical and device product development, approval, and maintenance. Representatives from FDA, Health Canada, NMPA (National Medical Products Administration), PMDA (Pharmaceuticals and Medical Devices Agency), EMA, MHRA (Medicines and Healthcare products Regulatory Agency) (Medicines and Healthcare products Regulatory Agency), European Health Authorities and ICMRA authorities, and other regulatory experts will provide global updates, insights, and discussion on current issues through interactive forums. Themes commonly revolve around global regulatory changes and impact on global development strategies, global harmonization/convergence and impact on drug development and advances and innovations to improve the practice of regulatory affairs, and regulatory hot topics.

TRACK 10

Regulatory CMC and Product Quality

The Regulatory CMC and Product Quality Track provides a comprehensive view of risk-based approaches across the product lifecycle. The track scope spans from the scientific understanding gained through product and process development to lifecycle expectations for global regulatory CMC submissions, CGMP (Current Good Manufacturing Practice), and Quality Systems. Sessions address the increasing regulatory complexity of development and manufacturing for worldwide markets, accelerated development timelines, new technologies, emerging regulations, and increased scrutiny of manufacturing operations and data.

TRACK 11

Statistics

This track will focus on topics related to the practice and application of statistical methods in medical product development throughout their lifecycle. Sessions will explore topics related to current statistical thinking which inform policy, regulation, development, review, and lifecycle management of medical products in the context of the current scientific and regulatory environments. A new aspect of the track is data science, a multidimensional area with the two major dimensions of curation and analysis. This track is focused on the analysis dimension, including analytics and predictive analytics.

TRACK 12

Value and Access

The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movement on all stakeholders: providers, payers, biopharma, and patients. Value and access to medicines are complex issues that require analysis from health, economic, and philosophical perspectives. The Value and Access track will bring together global regulators, industry leaders, academics, patients, and payers who will facilitate discussions and address questions such as:

- What information and evidence are being used to define value?
- What are the ethical considerations when determining access to medical products?
- Do strategies that increase diversity and inclusion in clinical trial research improve access to medicines? Who is making or influencing access decisions?
- How can real-world data be leveraged to drive access to medicines?
- What are the regulatory and legal considerations?

TRACK 13

Professional Development

The Professional Development track focuses its content on topics that improve and support ongoing personal growth for career and team success. This broad category includes interpersonal skills, soft skills, leadership, goal setting, life-long learning, career transitions (career growth, lateral career transitions, and entrepreneurship), social media/new media, and self-awareness to assess strengths and gaps.

DIAmond SESSIONS

DIAMOND SESSIONS

DIAmond Sessions represent rare opportunities for deeper connection with leaders in life sciences through insightful dialogue. Join us to help illuminate pathways and processes toward the interconnected future of global health.

DIA 2023 DIAmond Sessions will allow for deeper discussions into critical themes from the keynote plenary session. Expect thought-provoking conversations around some of the major themes of *DIA 2023*, including an exploration of diversity, AI and innovation— from cutting-edge technologies to novel approaches to research and development.

MONDAY
JUNE
26

Navigating the Constellation of Efforts to Increase Representation in Clinical Research

8:00-10:00AM EDT

Chair: Alexis Miller, JD, Executive Director, Global Regulatory Policy (US Lead), Merck

This DIAmond session will focus on the efforts to promote diversity, equity, and inclusion (DEI) in clinical research from a global perspective. It will include a presentation to set the stage, followed by a panel discussion with various experts working on DEI in the life sciences R&D industry. Attendees can expect to gain an understanding of the current efforts to promote diversity and inclusion in clinical research, the limitations of existing methods to describe outcomes, the complexities involved in collecting and assessing diversity and inclusion data, and the internal frameworks, processes, and best practices underlying clinical development plans. Attendees can also expect to gain insights into the global conduct of studies, the challenges of reconciling US requirements with global studies, and the limitations related to healthcare access.

TUESDAY
JUNE
27

Full Exposure: Artificial Intelligence to Advance, Replace, and Add Efficiency for Patient Benefit

9:00–10:15AM EDT

Chair: Alison Cave, PhD, Chief Safety Officer, The Medicines and Healthcare products Regulatory Agency (MHRA)

The health and life sciences industry is on the verge of a transformation driven by powerful artificial intelligence (AI) tools and language models such as GPT. These technologies can enable novel applications in domains such as drug discovery, medicines safety, and patient communication. However, they also pose significant challenges in terms of trust, transparency, bias, ethics, validation, and regulation. How can we harness the potential of generative and other forms of AI while addressing these challenges?

This session will provide an overview of the current and future state of large language processing and other AI techniques, and how they can impact the future of health.

WEDNESDAY
JUNE
28

A Case Study for Illumined Therapeutic Development: Shining the Light on ALS

9:00-10:15AM

Chairs: Peter Sorger, PhD, Head of Therapeutic Science, Harvard Medical School

The range of treatment modalities now available is promising for patients but frameworks to guide prioritization of development are lacking. Considerations before developing a new approach include benefit/risk, patient preferences, manufacturing, technology and data use, and payment and access. This session will examine these issues through the lens of a case example and include discussion of clinical applications and clinical reality, patient perspectives, regulatory considerations, and current and future clinical development pipeline(s).

THURSDAY
JUNE
29

FDA Town Hall

11:15AM-12:15PM

Chair: Courtney Granville, PhD, MSPH, Director, Scientific Affairs, DIA, United States

The FDA Town Hall is the forum to hear from FDA leadership about Center priorities. This year we will include discussions and updates from our speakers on these priorities as well as efforts to improve implementation of diversity, equity, and inclusion (DEI) in clinical trials, the impact of AI on regulatory submissions and review, and efforts to continue to create access to innovative therapies across FDA. The audience will be invited to submit questions of general interest.

SCHEDULE AT-A-GLANCE

MONDAY, JUNE 12-THURSDAY JUNE 15

Pre-Conference Short Courses (Virtual)

Schedule

9:30AM-12:30PM	Half-Day Morning Pre-Conference Short Courses*
1:00-4:00PM	Half-Day Afternoon Pre-Conference Short Courses*

SATURDAY, JUNE 24

Registration Hours

8:00AM-5:00PM	Exhibitor Registration

SUNDAY, JUNE 25

Registration Hours

8:00AM-5:00PM	Attendee, Speaker, and Exhibitor Registration

Pre-Conference Short Courses

9:00AM-5:00PM	Full Day Pre-Conference Short Courses*

*Space is limited for Pre-Conference Short Courses.

MONDAY, JUNE 26

Registration Hours

8:00AM-6:00PM	Attendee, Speaker, and Exhibitor Registration

Schedule

8:00-9:00AM	Coffee Service
8:00-8:45AM	Annual Meeting Orientation
9:00-10:30AM	Opening Plenary
10:45-11:45AM	DIAmond and Educational Sessions
11:30AM-6:15PM	Exhibit Hall Open
11:45AM-1:15PM	Luncheon Service (Exhibit Hall)
	Community Networking Zone Seating for Lunch (Exhibit Hall)
12:00-1:30PM	Professional and Student Posters
	Innovation Theater Presentations (Exhibit Hall)
	Content Hubs
	Community Roundtable Discussions
1:30-2:30PM	Educational Sessions
2:30-4:15PM	Refreshment Break (Exhibit Hall)
	Innovation Theater Presentations (Exhibit Hall)
	Content Hubs
	Community Roundtable Discussions
2:45-4:15PM	DIAmond Solution Session (Invite Only)
4:15-5:15PM	Educational Sessions
5:15-6:15PM	Exhibit Hall Reception

TUESDAY, JUNE 27

Registration Hours

8:00AM-5:15PM	Attendee, Speaker, and Exhibitor Registration

Schedule

8:00-8:30AM	Coffee Service
8:30-9:30AM	DIAmond and Educational Sessions
9:30AM-5:00PM	Exhibit Hall Open
9:30-10:30AM	Coffee Break (Exhibit Hall)
	Innovation Theater Presentations (Exhibit Hall)
10:30-11:30AM	Educational Sessions
10:30-12:00PM	DIAmond Solution Session (Invite Only)
11:30AM-1:00PM	Luncheon Service (Exhibit Hall)
	Community Networking Zone Seating for Lunch (Exhibit Hall)
	Professional Posters
11:45AM-1:15PM	Innovation Theater Presentations (Exhibit Hall)
	Content Hubs
	Community Roundtable Discussions
1:15-2:15PM	Educational Sessions
2:15-4:00PM	Refreshment Break (Exhibit Hall)
	Innovation Theater Presentations (Exhibit Hall)
	Content Hubs
	Community Roundtable Discussions
4:00-5:00PM	Educational Sessions

WEDNESDAY, JUNE 28

Registration Hours

8:00AM-5:15PM	Attendee, Speaker, and Exhibitor Registration

Schedule

8:00-8:30AM	Coffee Service
8:30-9:30AM	DIAmond and Educational Sessions
9:30AM-4:00PM	Exhibit Hall Open
9:30-10:30AM	Coffee Break (Exhibit Hall)
	Innovation Theater Presentations (Exhibit Hall)
10:30-11:30AM	Educational Sessions
10:30-12:00PM	DIAmond Solution Session (Invite Only)
11:30AM-1:00PM	Luncheon Service (Exhibit Hall)
	Community Networking Zone Seating for Lunch (Exhibit Hall)
11:45AM-1:15PM	Innovation Theater Presentations (Exhibit Hall)
	Content Hubs
	Community Roundtable Discussions
1:15-2:15PM	Educational Sessions
2:15-4:00PM	Refreshment Break (Exhibit Hall)
	Innovation Theater Presentations (Exhibit Hall)
	Community Roundtable Discussions
4:00-5:00PM	Educational Sessions

THURSDAY, JUNE 29

Registration Hours

8:00-11:00AM	Attendee and Speaker Registration

Schedule

8:00-8:30AM	Coffee Service
	Community Roundtable Discussions
8:30-9:30AM	Educational Sessions
9:45-10:45AM	DIAmond and Educational Sessions
10:45-11:15AM	Coffee Break
11:15AM-12:15PM	FDA Town Hall

DIA 2023 IS DESIGNATED AS A "PATIENTS INCLUDED" EVENT

We're proud to announce that the *DIA 2023 Global Annual Meeting* is designated as a "Patients Included" meeting!

This means that we are committed to incorporating the experience of patients as experts in living with their condition while ensuring they are neither excluded nor exploited.

For more information, visit the Patients Included website.

DIA and the Global Annual Meeting Program Committee have assessed that the program successfully meets all five of the Patients Included charter clauses:

Patients or caregivers with experience relevant to the meeting's central theme actively participate in the design and planning of the event, including the selection of themes, topics, and speakers.

- The *DIA 2023* program agenda has been structured to incorporate the patient perspective within a dedicated Patient Engagement Track. The Program Committee includes patient representatives, who have responsibility for building the Patient Engagement track, advising on appropriate inclusion of patient perspectives in sessions throughout all 13 educational tracks, and serving as resources to identify qualified patient speakers.
- As speakers, patients invited to speak in sessions will receive complimentary registration.
- DIA facilitates the attendance of patients or patient partners at the *DIA 2023 Global Annual Meeting* through the Patient Partners Program.
- In addition, *DIA 2023* offers a special registration fee for patients and patient organization representatives of $265 if registered by May 19. After May 19, the standard patient registration rate of $425 will apply. Access the Patient Registration Form.

Patients or caregivers with experience of the issues addressed by the event participate in its delivery and appear in its physical audience.

- Patients and Patient Partners with experience or interest in furthering the impact of their involvement in medical product development are featured as speakers, panelists, and discussants throughout the program.
- The Patient Partners speaker initiative assists the Program Committee and session developers with finding the right patient and/or Patient Partner to speak in the program.

The disability requirements of participants are accommodated. All applicable sessions, breakouts, ancillary meetings, and other program elements are open to patient delegates.

- *DIA 2023* will be held at the Boston Convention and Exhibition Center, 415 Summer Street, Boston, MA. The facility features accessible entrances, registration and open areas, meeting rooms, parking, and provides assistive devices. In addition to the Boston Convention and Exhibition Center, DIA has reserved sleeping room blocks at special conference rates in hotels surrounding the convention center. A complete list of hotels can be viewed here. For specific questions, please contact the hotel directly.

Virtual access is guaranteed before and after the meeting.

- The hashtag **#DIA2023** will be actively promoted prior to and during the event across social media platforms so participants, as well as those unable to attend the event, can join the conversation and discuss presentations and key takeaways.
- DIA will post speaker presentation slides to the DIA website prior to the meeting and for six months after the meeting for viewing and downloading by attendees.

If you have any questions, please contact us at CustomerService@DIAglobal.org or 1.888.257.6457.

DIA 2022 GLOBAL ANNUAL MEETING ATTENDANCE STATS

Top 5 Job Roles by Attendee



Attendees by Role



Product Responsibility



Why Should You Attend?

5,000+ Global Attendees

200+ Global Attendee Sessions

9.1 M Impressions on Social Media

Top 30 Biopharmaceutical Companies Participate

DIA Community Expansion Through Social Media

LinkedIn	Facebook	Twitter
2019: 16,296	2019: 12,986	2019: 9,201
2022: 25,718	**2022: 9,310**	**2022: 13,667**

Followers in 2023
63,000

Features

- Diamond Sessions
- Pre-Conference Short Courses
- Community Roundtables
- Content Hubs
- Innovation Theaters
- Networking
- Student and Professional Posters

13 Tracks

- Clinical Safety and Pharmacovigilance
- Clinical Trials and Clinical Operations
- Data and Technology
- Medical Affairs and Scientific Communication
- Patient Engagement
- Translational Sciences and Precision Medicine
- Project Management and Strategic Planning
- R&D Quality and Compliance
- Regulatory
- Regulatory CMC and Product Quality
- Statistics
- Value and Access
- Professional Development